Latest Reimbursement News

Lumos Diagnostics has increased live FebriDx sites to 215 and moved two additional top 100 US urgent care groups into network rollout across more than 40 sites. Two further health-system-owned groups are validating the test across more than 45 sites, but the announcement does not disclose contract values or guaranteed purchase volumes.

PolyNovo delivered 16.1% revenue growth and a sharp improvement in operating cash flow in FY26, despite a lower statutory profit after a prior-year tax benefit and a fire-related write-off. The ASX-listed wound-care company now expects to lodge its U.S. PMA application for NovoSorb BTM before the end of 2026.

JPMorgan Emerging Markets Research Enhanced Index Equity Fund nearly trebled its net assets in 2026 after attracting $48.5 million of applications and recording a $4.6 million profit. The growth came with a sharp increase in exposure to one underlying emerging markets ETF.

JPMorgan Global Research Enhanced Index Equity Trust reported a sharp rise in operating profit and net assets for the year ended 30 June 2026, powered largely by fair value gains across its global portfolio. Distributions also increased substantially, particularly for hedged classes, although the report does not show whether the Fund outperformed its benchmark.

Pacific Edge is positioning Cxbladder for a Medicare-led recovery, but the company remains loss-making with NZ$7.8 million in net cash after a difficult FY26. The investment case now turns on final US coverage, test volumes and whether the enlarged balance sheet can carry the business to scale.

Telix’s Pixclara has become the first FDA-approved FET-PET imaging drug for glioma, opening a new US diagnostic pathway for adults and children. The approval is commercially significant, but pricing, reimbursement and launch timing remain undisclosed.

Emyria has secured a limited in-person speaking position at a US FDA hearing examining how psychedelic medicines could be delivered safely and at scale. The appearance gives the ASX-listed company a regulatory platform, but does not represent FDA approval, funding or a commercial agreement.

Bannerman Energy has completed a fully underwritten A$124 million institutional placement, giving the Etango uranium project a funding pathway through construction and ramp-up. The company now turns to a targeted Q4 2026 Final Investment Decision, while a further non-underwritten shareholder offer could raise up to A$10 million.

St Barbara will sell its remaining New Simberi interest and Tabar Islands exploration exposure to Lingbao for A$453 million in cash, while retaining royalties over future production. The deal could leave the gold developer with about A$880 million in cash, but completion still depends on regulatory and potentially shareholder approvals.

Bannerman Energy has launched a fully underwritten A$124 million placement that it expects will fund its share of the Etango uranium project through construction and ramp-up. The raising follows confirmation that CNOL’s strategic investment and joint venture conditions have been satisfied or waived.

Viridis Mining and Minerals has secured approval for a R$77.5 million BNDES financing facility, reducing the estimated senior debt still required for its Colossus rare earth project to about US$280 million. The 16-year facility carries an indicative current cost of approximately 4.8% and supports the project’s Brazilian processing and research infrastructure.

FBR has fully underwritten its A$2.5 million share purchase plan, removing the immediate risk of an unfunded shortfall but adding cash fees and potential option dilution. Alpine Capital can also terminate the arrangement in several circumstances, including a 10% fall in the S&P/ASX 200 Index.